Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder Jr Acquires 60,000 Shares

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 60,000 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were bought at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the transaction, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This represents a 162.48% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zenas BioPharma Stock Down 7.8%

Shares of ZBIO stock traded down $1.43 during mid-day trading on Monday, reaching $16.91. 1,163,015 shares of the company were exchanged, compared to its average volume of 497,699. Zenas BioPharma, Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The company has a market capitalization of $1.07 billion, a P/E ratio of -2.00 and a beta of -0.61. The business’s 50 day simple moving average is $21.04 and its 200 day simple moving average is $26.62.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter last year, the company posted ($0.80) EPS. Research analysts predict that Zenas BioPharma, Inc. will post -4.25 earnings per share for the current year.

Institutional Investors Weigh In On Zenas BioPharma

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in Zenas BioPharma in the fourth quarter valued at $38,000. Quarry LP lifted its stake in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma in the third quarter valued at $30,000. CWM LLC raised its stake in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zenas BioPharma during the fourth quarter valued at about $95,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research report on Thursday. Guggenheim raised their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Finally, Morgan Stanley raised their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $44.29.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.